Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents by Helwig, K. et al.
Micropollutant point sources in the built environment: identification and monitoring of
priority pharmaceutical substances in hospital effluents
Helwig, Karin; Hunter, Colin; MacLachlan, John; McNaughtan, Moyra; Roberts, Joanne;
Cornelissen, Alex; Dagot, Christophe ; Evenblij, Herman; Klepiszewski, Kai; Sven, Lyko;
Nafo, Issa; McArdell, Christa; Pahl, Ole
Published in:






Publisher's PDF, also known as Version of record
Link to publication in ResearchOnline
Citation for published version (Harvard):
Helwig, K, Hunter, C, MacLachlan, J, McNaughtan, M, Roberts, J, Cornelissen, A, Dagot, C, Evenblij, H,
Klepiszewski, K, Sven, L, Nafo, I, McArdell, C & Pahl, O 2013, 'Micropollutant point sources in the built
environment: identification and monitoring of priority pharmaceutical substances in hospital effluents', Journal of
Environmental & Analytical Toxicology, vol. 3, no. 4, pp. 1-10. https://doi.org/10.4172/2161-0525.1000177
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 29. Apr. 2020
Research Article Open Access
Volume 3 • Issue 4 • 1000177
J Environ Anal Toxicol
ISSN: 2161-0525 JEAT, an open access journal
Open AccessResearch Article
Environmental & Analytical 
Toxicology
Helwig et al., J Environ Anal Toxicol 2013, 3:4
http://dx.doi.org/10.4172/2161-0525.1000177
*Corresponding author: Ole Pahl, School of Engineering and Built 
Environment, Glasgow Caledonian University, Cowcaddens Road, Glasgow, 
G4 0BA, UK, E - Mail: O.Pahl@gcu.ac.uk
Received May 17, 2013; Accepted July 08, 2013; Published July 10, 2013
Citation: Helwig K, Hunter C, MacLachlan J, McNaughtan M, Roberts J, et al. 
(2013) Micropollutant Point Sources in the Built Environment: Identification and 
Monitoring of Priority Pharmaceutical Substances in Hospital Effluents. J Environ 
Anal Toxicol 3: 177. doi:10.4172/2161 - 0525.1000177
Copyright: © 2013 Helwig K, et al. This is an open - access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Micropollutant Point Sources in the Built Environment: Identification and 
Monitoring of Priority Pharmaceutical Substances in Hospital Effluents
Helwig K1, Hunter C1, MacLachlan J1, McNaughtan M1, Roberts J1, Cornelissen A2, Dagot C4, Evenblij H3, Klepiszewski K2, Lyko S5, Nafo I5, 
McArdell CS6, Venditti S2 and Pahl O1*
1School of Engineering and Built Environment, Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 0BA, UK
2Resource Centre for Environmental Technologies, Public Research Centre Henri Tudor, 66 rue de Luxembourg, L - 4221 Esch - sur - Alzette, Luxembourg
3Waterschap Groot Salland, Dokter van Thienenweg 1, 8025 AL Zwolle, Netherlands
4Responsable Spécialité, Eau et Environnement, ENSIL - GRESE, Université de Limoges, Parc ESTER Technopole, 16 rue Atlantis, 87068 LIMOGES CEDEX, France
5Emschergenossenschaft, Kronprinzenstraße 24, 45128 Essen, Germany
6Eawag, Swiss Federal Institute of Aquatic Science and Technology, Überlandstrasse 133, CH - 8600 Duebendorf, Switzerland
Keywords: Pharmaceuticals; Micropollutants; Point sources; 
Hospitals; Prioritisation; Monitoring
Abbreviations: AF: Assessment Factor; ICM: Iodized Contrast 
Media; MEC: Measured Environmental Concentration; NOEC: No 
Effect Concentration; PEC; Predicted Environmental Concentration; 
PNEC: Predicted No-Effect Concentration; PPCP: Pharmaceutical and 
Personal Care Products; WWTP: Waste Water Treatment Plant.
Introduction
In recent years there has been increasing attention towards 
identification, effect and abatement of micropollutants in the aquatic 
environment, such as residues of pharmaceutical and personal care 
products (PPCPs). These micropollutants in general originate from 
urban - or built - environments, are collected in waste water catchment 
and treatment systems and may finally reach the aquatic natural 
environment [1-12]. These residues are typically found at very low 
concentrations and are unlikely to affect human health. However, 
their continuous release causes chronic exposure to aquatic organisms. 
Concerns have also been raised over increased bacterial resistance to 
antibacterials released into the environment [13,14].
With an increasing requirement to account for - and reduce - 
these micropollutants, there is an increasing need to identify priority 
substances, so that urban waste water discharges can be characterised 
by their pollutant load. This characterisation can aid the development 
of suitable tactics to protect the aquatic environment from the adverse 
effects of these discharges. In general, PPCPs are released into the 
aqueous environment during the manufacturing process, disposal, 
and as excreted residue. Studies showed that in China and India the 
manufacturing industry contributes significantly to this problem 
[15,16], and recent European studies showed that disposal down the 
drain requires further attention [17,2]. Still, it is generally assumed that 
in Europe, excreted residue is the most significant source [17], whether 
that is in a hospital or in the community. 
Based on the aforementioned reasons, there have been 
considerations regarding the separate collection and (advanced) 
treatment of wastewater at point sources in urban areas - especially 
health care installations - based on relative contributions [6], and 
economic considerations on related cost and carbon emissions [18].
In this perspective, a project entitled “Pharmaceutical Input and 
Elimination from Local Point Sources” (PILLS) sought to address 
this debate in a partnership of research institutes, water boards and 
universities in six European Countries. This consists of (i) developing 
a method for the identification of suitable priority substances for the 
specific point source of interest (hospitals), (ii) monitoring the identified 
priority substances in hospital effluents in a range of geographical areas, 
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both rural and urban, and (iii) trialling advanced treatment of hospital 
effluent. This paper describes the development of a method for the 
identification of priority substances and results from the subsequent 
monitoring campaigns. It outlines difficulties encountered during the 
implementation but argues that the results per se are of importance for 
decision makers in the urban environment, and that the method can be 
adopted universally to identify key substances for monitoring in other 
built environment sectors.
Methods
Identification of priority substances
In this study, we argue that the underlying key criterion for 
selection of priority substances should be resultant environmental risk 
rather than prioritisation based on single factors such as highest mass, 
highest number of prescriptions or toxicity of substances alone. In the 
context of pollution, environmental risk is normally defined as the 
combination of three dimensions: presence of substances (predicted or 
measured concentrations in the environment), their toxicity (normally 
tested for a range of organisms on various trophic levels) and their 
persistence in the environment (e.g. are they biodegraded naturally or 
removed in waste water treatment plants WWTP) [19].
The first step in the assessment of environmental (pollution) risk 
normally involves drawing up an inventory of substances that are 
either measured or predicted to be in the environment in significant 
quantities. The second step examines the concentration of substances 
in relation to their specific toxicity: relatively low concentrations of 
highly toxic substances can have a higher ‘significance’ than large, often 
headline - grabbing concentrations of relatively benign substances. 
The third step in the assessment is again closely linked with the 
previous step in that it addresses the question of whether the identified 
substances are persistent in the environment, so that their toxicity 
can have an effect on the natural environment. There is obviously a 
clear link between persistence and presence, in that some substances, 
for example amoxicillin, degrade quickly in the environment or even 
within the sewage network, whereas others, e.g. carbamazepine, 
show little degradation in WWTPs. However, it is still important to 
conduct this third step for all substances because for many of these 
the assessment of their ‘presence’ in the environment will be based 
on consumption data rather than measured concentrations in the 
environment, and their metabolites and degradation products may 
be important even if the parent compound is no longer present [20]. 
Another point of importance is to distinguish between substances that 
can be removed by conventional, existing waste treatment technologies 
as can be found in most sewage works (e.g. solids removal and 
biological treatment including nitrification/denitrification) and those 
substances that are not removed by this conventional treatment: they 
are most likely to enter the natural environment and thus fully develop 
their toxic potential.
This ‘3D’ identification of priority substances for monitoring or 
removal is described in more detail below, both generically and in 
implementation in the project.
Step 1. Presence: what is there?
Even though the project partners represented regions that are 
deemed to be similar, i.e. “North West Europe” as defined by the 
European Union, there is considerable difference in the approach 
to water treatment in these countries. For example, sewage sludge 
recycling to land is generally supported within the European Union 
area [3], and between 50% and over 80% of sewage sludge in Scotland 
and the UK, respectively, is applied to farmland [21,22]. In many 
other areas local concern about pollution does not allow this practice 
and in Switzerland application of sewage sludge to land is prohibited 
[23]. Similarly, in Switzerland environmentally relevant works serving 
above 100,000 population equivalent have to demonstrate efficient 
removal of particulates by tertiary treatment - using filtration as a 
minimum [24] whereas in other areas most WWTPs incorporate only 
conventional secondary biological treatment. Such different practices 
will consequently have an effect on micropollutants in waste water 
and receiving waters: whereas in one region certain substances will 
be removed with the sewage sludge and destroyed by incineration, 
in other regions they may find their way into water courses following 
land - application of sludge. It is therefore dependant on the region to 
consider whether the aquatic phase of waste water alone is of interest 
or if the sorbed fraction of pharmaceutical residue merits attention as 
well [25].
This step starts with a review of relevant literature. The main point 
here is to ensure that all the relevant components are captured before 
any screening takes place along the other two dimensions of the ‘3D’ 
risk assessment. In cases where the resultant list of possible substances 
for further assessment becomes too long (there are some 3,000 
pharmaceutical substances registered in the EU), an interim process at 
this point may be to draw up a shortlist for further assessment based 
on a common denominator approach: substances are chosen based on 
frequency of their inclusion in other reports, priority lists etc. This part 
of the assessment would normally include a review of consumption 
data, such as statistics on products sold or in the case of this project 
prescribed to patients. It is also important at this point to consider the 
ratio of consumed over released over consumed? Many substances 
are metabolised in the human body and thus ‘used up’ or excreted as 
metabolites, and waste or out - of - date substances may be released 
into the solid - instead of liquid - waste stream, depending on user 
behaviour and preferences [26].
However, it became obvious very early on in the project that the 
required information in the form of specific consumption data and a 
complete list of all compounds used was simply not available for all 
hospitals, a problem that was also outlined by Schirmer et al. [19], for 
hydrogeological studies.
Faced with this significant uncertainty as regards prescription 
practice and prescribed volumes (especially in different regions), the 
approach was to start with a mix of published data and ‘expert input’. 
Much of this ‘expert choice’ is not easily scientifically substantiable, 
as it may refer to personal experience or regional data that is not 
published. However, we also considered the number of times at which 
a substance was chosen by experts and appears on other prioritisation 
lists. This approach in itself - although not the only parameter in 
our approach is documented in the key paper by deVoogt et al. [27]. 
In terms of published data across Europe, several substances have 
received particular attention, the most prominent being the proposed 
inclusion of diclofenac as a Priority Substance in Annex II of the 
Priority Substances Directive EC/105/2008 in January 2012. An earlier 
draft also included diatrizoate, carbamazepine and iopamidol. Several 
other organisations and authors also prioritised compounds for 
environmental monitoring and they represent the bulk of the published 
data consulted (Table 1).
Another concern in the initial screening is the question of whether 
all relevant therapeutic groups of substances should be included in the 
shortlist of substances selected for further evaluation. In the context 
of hospital effluents, this approach may lead to ‘forced’ inclusion of 
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drugs into the hospital with them). These issues apply less to permanent 
residents, such as in geriatric and psychiatric hospitals, who normally 
excrete all residue from medicines administered there. 
Hospital contribution: The relative contribution of hospitals 
compared to domestic use was relevant to the selection process for this 
work. If a drug removal rate can be improved by advanced treatment, 
but the hospital contribution for this drug is small compared to the 
domestic contribution, the compound was of less interest to the 
project as the reduction in environmental concentration achieved by 
treating hospital effluent would still be small. However, a hospital’s 
contribution to pharmaceutical load (total mass) is not necessarily the 
same as its contribution to aquatic toxicity. Cytostatics, for example, 
are considered highly toxic at low concentrations whereas heavy 
contrast media are toxicologically not relevant [30].
In the EU, the average number of hospital beds per 10,000 heads 
of the population varies from 35 (Denmark and Portugal) to 83 
(Germany), so an even pharmaceutical usage for hospital patients 
and non - hospital patients alike would account for 0.4 - 0.9% hospital 
contribution.
Of course, the hospital fraction for some drugs is much larger 
and overall hospitals are estimated to account for 20 - 25% of all 
human medicine usage [31,32], although the hospital fraction varies 
per drug. Whilst hospitals are generally seen as a hotspot especially 
for antibacterials [33], in Germany, for total antibacterials hospital 
contribution does not exceed 25% [34], with cephalosporins and 
penicillins in particular showing a relatively high hospital fraction [6]. 
For iodized contrast media (ICM) it is estimated to be about 50% [6]. 
Hospital consumption of cytostatics is also relatively high even though 
it is important to distinguish between consumption and excretion: 
Weissbrodt et al. [32], note that 70% of cytostatics and 50% of ICM 
consumed in hospitals are administered to outpatients and therefore 
likely to be excreted in the community. Ort’s (2010) measurements 
of residues in WWTP and hospital wastewater gave low values for 
the hospital contributions for all drugs apart from trimethoprim 
and roxithromycin <15%. A study by Escher [30], found that for the 
WWTP monitored, around 38% of the total pharmaceutical load in 
the WWTP stems from the regional hospital connected to the plant. 
Specialised (e.g. psychiatric and geriatric) hospitals are likely to use 
quite a different range of drugs than general hospitals. In rural areas 
without large population centres, large hospitals with a full range of 
treatment facilities may be encountered in smaller towns, where they 
will serve a population much greater than the town.
Step 2. Toxicity: how dangerous is it?: Assessment of the toxic 
some substances simply by treatment group - possibly at the risk of 
excluding other substances by ‘over - represented’ treatment groups. 
In cytostatics, for example, a similar pharmaceutical action does not 
always correspond with a similar chemical structure or a similar level 
of toxicity [28]. Additionally, drugs may be indicated for more than 
one condition. The Global Water Research Coalition (GWRC) priority 
setting does not use representativeness of a drug group as a selection 
criteria, as “...from a scientific point of view there is no need for all 
different classes of pharmaceutical to be represented in the final priority 
list” [27]. However, proposals for amendments to ‘Directive 2001/83/
EC with respect to Information to Patients, Pharmaco - vigilance and 
Counterfeit Medicines’ include extension of the pharmaco - vigilance 
concept to include not only public health and patient health but also 
the environment [29]. In other words, medical professionals could 
be asked to take environmental effects into account alongside public 
and patient health when prescribing. Treatment class is then clearly 
relevant. Furthermore, pharmaceutical class might indicate relative 
hospital usage. Kümmerer [6], notes cytostatics are mostly used in 
hospitals; contrast media and anaesthetics may also be considered 
typical ‘hospital drugs’ (although they may be administered to 
outpatients) whereas medication for chronic complaints is likely to be 
predominantly used in the community. 
Although contrast media are technically not pharmaceutically 
active, they were considered relevant to the project objectives as 
they are used in high quantities and are defined as pharmaceutical 
substances (for diagnostics). On the other hand, several other non - 
pharmaceutically active compounds, e.g. saline solution, were excluded 
as these fell outside the scope of the project.
Excretion: Most drugs are designed to be persistent e.g. during 
stomach transfer but all will eventually be excreted either directly or 
in the form of metabolites or degradation products. The extreme of 
this are contrast media which tend to be excreted 100% unchanged. 
Excretion rates for the same active compound may vary with the 
method of administration. Topical products such as creams and gels 
will have different excretion rates and furthermore, a certain amount 
of these products is washed off, or rubs off on sheets and enters the 
wastewater stream via laundry. A high excretion rate, indicating that a 
large proportion of the parent compound reaches the sewer, increases 
the relevance of the compound to the project.
A significant proportion of drugs dispensed in hospitals may 
be issued to outpatients and not be excreted within the hospital 
environment. Conversely, patients excrete residues of drugs prescribed 
by their general practitioner in the hospital (and may indeed bring such 
Topic area Sources
Active Drug Ingredients, Antibiotics and X - Ray contrast agents in sewage discharges and 
surface waters in Saxony, Germany Engelmann and Rohde, 2009
Pharmaceutical residues in the assessment of environmental quality and state of the 
environment in Germany Sattelberger, 1999
Source, fate and effect of pharmaceuticals in the environment in Germany LANUV/IWW, 2007
Human pharmaceuticals in aquatic ecosystems – an approach for the assessment of 
ecotoxicological risk of pharmaceutical residues Hanisch et al., 2004
Removal of selected Pharmaceuticals in Sewage Treatment Plants in Italy Castiglioni et al., 2006
Micropollutants detected in the river Rhine ICPR, 2007
Review of actions on priority substances identified in background documents adopted by 
OSPAR (2007) OSPAR (2007
Targeted Monitoring Programme for Pharmaceuticals in the Aquatic Environment in England Environment Agency, 2003
Emerging pollutants including pharmaceuticals, hormones, personal care products, disinfectants 
and industrial compounds 
Umweltbundesamt, 2006; Götz et al., 2010; UBA, 2011; Bergmann, 
2011; Fick et al., 2012
Table 1: Type of literature sources consulted in the method development.
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Sewage treatment plays an important role in the removal 
of pharmaceuticals from waste water [39]. The extent to which 
pharmaceuticals are removed is compound - specific and depends 
primarily on the treatment processes applied and secondly on process 
parameters [40-45], although removal rates show considerable 
variability between samples from the same plant and between 
plants [44,46]. High concentrations of pharmaceuticals may inhibit 
biodegradation in wastewater treatment. However, Joss et al. [47], 
expect dilution of municipal wastewater (e.g. by extraneous water) to 
reduce the degree of biological removal and states that “wastewater 
segregation and treatment at the source are therefore to be favoured 
for elimination of persistent micro - pollutants over centralized end - 
of - pipe treatment” [47]. 
In most EU countries sewage is treated by conventional mechanical 
and biological processes, where aerobic biodegradation and sorption 
onto solids are the most important removal mechanisms [48]. Although 
values for elimination by these processes are well documented in the 
literature, they vary considerably between different studies (Table 2). 
Monitored Hospitals
Germany
The German case study hospital was located in middle - west 
Germany, in the city of Gelsenkirchen, and is one the biggest hospitals 
in the densely populated Ruhr area. This university teaching hospital 
was built in 1972, has 560 beds, about 1,200 employees and up to 75,000 
in - and out - patients per year. The hospital offers the whole range 
of medicinal services, i.e. internal medicine (cardiology, hematology, 
gastro - enterology), oncology, surgery, gynecology, otolaryngology, 
pediatrics (neonatology), orthopedics, urology, nuclear medicine, 
and radiology, including computer tomography (CT) and magnetic 
resonance tomography (MRT). The fresh water consumption of the 
hospital was 200 m3 day-1 in 2010, with impervious areas disconnected 
from the combined sewer system so that rainwater inflow to the sewer 
was reduced to a minimum. 
The Netherlands
The Dutch case study hospital was located in Zwolle and was the 
5th largest non - academic hospital in the Netherlands. It employs 
5,700 people, has 1,076 beds, 470,000 polyclinic visits and 40,000 
hospitalisations per year. Wastewater flow was estimated to be 240 m3 
day-1 in 2010.
Switzerland
The Swiss case study involved a typical, regionally important 
effect of a substance is, as mentioned before, closely linked to the 
previous steps. The intrinsic toxicity of a substance provides little 
information on the toxic effect in the receiving environment unless it 
is combined with information on the concentration and persistence 
of the substance in the environment. Some substances, e.g. contrast 
media, are released in large quantities, and have high environmental 
persistence, but low toxicity. Other substances might be extremely toxic 
per unit mass, but are released into the environment only in small doses. 
Consequently, it is the substances that have the highest combination of 
toxicity and presence that are likely to create the largest toxic effect 
in the environment. This combination is generally expressed as the 
ratio of a substance’s predicted environmental concentration (PEC), 
extrapolated from consumption data, or measured environmental 
concentration (MEC) and its predicted no - effect concentration 
(PNEC). Substances that have a ratio of 1 or greater are likely to 
cause environmental effect. Unfortunately, there is a large amount of 
uncertainty regarding both the PEC and PNEC for most compounds. 
Data on environmental effects are often limited to acute toxicity to 
standard organisms and lack information on chronic and specific 
toxic effects [35]. The latter data would be of interest because, beside 
acute emissions of pharmaceuticals by combined sewer overflows, a 
significant amount of substances enter the environment continuously 
via WWTP effluents, so that aquatic organisms are chronically exposed 
to low doses. Aside from lethal effects after long - term exposure, other 
effects, such as developmental, behavioural or reproductive effects 
are likely to occur and organisms at different trophic levels may be 
affected [36]. Furthermore, organisms are rarely exposed to a single 
pharmaceutical but rather to a cocktail of pharmaceutical residues 
in varying concentrations. The toxicity of such a cocktail cannot be 
calculated from the individual toxicities of compounds in the mix and 
may well exceed their combined effects [37,38]. 
In the EMEA guidelines [36] toxicity is expressed as the PNEC 
of three trophic levels and derived from tests for acute toxicity or 
from No Effect Concentrations [NOEC] tests for chronic effects. An 
Assessment Factor [AF] is used to express a degree of uncertainty for 
the comparison of acute and chronic toxicity, with AF being 1000 for 
acute toxicity and 10 or 50 for NOEC values. Even though significant 
progress has been made in the last decade and PNEC values based 
on the EMEA guidelines can be found in the literature for many 
substances, they can vary by several orders of magnitude between 
studies, and this adds a further level of uncertainty. Normally, the 
lowest value found should be used under the precautionary principle. 
However, the choice of endpoint (which species, which type of effect) 
is also affected by decision making processes (e.g. which endpoint is 
perceived as important by scientists, environmentalists, the general 
public). Similarly, ecotoxicological effects and uncertainties should 
be evaluated carefully in decision making processes where removal is 
offset against, for example, environmental impact of the WWTP or a 
range of environmental factors (e.g. carbon emissions).
Step 3. Persistence: how long does it stay?: Persistence and mobility 
of substances post excretion into the environment can be influenced 
by natural breakdown, breakdown in waste water treatment plants 
(WWTP), or by the tendency of substances to remain waterborne or 
to attach to solids, which are less mobile. Many substances break down 
naturally in the complex matrix of organic or inorganic materials and 
microbes in municipal sewerage. Some may sorb onto solids particles, 
and thus are removed from the waste water stream by relatively simple 
processes such as sedimentation, whereas other substances have a 
tendency to stay in the aqueous phase. These substances have the 
highest potential to be persistent and mobile in the receiving water 
environment, where they could have a toxic effect.
Kd [L kgss-1] (for sorption onto solids)
Kbiol [Ld - 1g - 1] (for 
biodegradation)
Diclofenac 16, 20, <30, 118 - 151,118 - 32, 710 0.04, 1.2
Naproxen 20, 11 - 51, <30, 217, 630 1, 9
Carbamazepine 1, 17, 25, 50, 20 - 68, 36 - 65, 150, 135 - 314 <0.06, 0.007
Atenolol 0, 38, <50, 10 - 95, 1600 0.69, 1.9, 1.5
Bezafibrate 0, 170 1.8, 3.3
Ciprofloxacin 450, 20000
Clarithromycin 262, 280
Sulfamethoxazole 3 - 77, 29, <30, 6 - 62, 80, 256, 370 0.3
Erythromycin 165, 11 - 309 6
Iopromide 11, 5 - 30 1.8
Cyclophosphamide 2, 1800
Table 2: Examples of literature values on parameters determining the removal 
rates in municipal wastewaters (from Kovalova, 2012).
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general hospital in Switzerland in the canton of Aargau, with 346 used 
beds serving more than 250,000 inhabitants [45]. In 2009, there were 
126,328 “days of care” and 17,163 patients leaving the hospital. The 
whole range of medical services was offered, e.g. internal medicine, 
oncology, surgery, maternity clinic, nuclear medicine, and radiology, 
including CT and MRI. In 2009, 233 m3 day-1 of water was used in 
the main hospital wing that hosts patients, where pharmaceuticals 
are excreted. At this location, the wastewater from the restaurant was 
included, but not that from the laundry facility. (Detailed monitoring 
results not reported in this paper.)
Luxembourg
The Luxembourg hospital was located in Esch - sur - Alzette. It 
has 360 beds, and in 2010 total water consumption was around 201 
m3 day-1, of which 141 m3 day-1 was used in the main clinical hospital. 
Effluent sampling represented departments of surgery, maternity, 
oncology, psychiatry, urology, internal medicine, intensive care unit 
and addiction medicine, with a total of 211 beds and an average 84% 
occupation rate.
United Kingdom
Monitoring in the UK comprised two locations in Scotland, 
namely the densely populated Glasgow area and a small town in the 
rural Scottish Borders area. In each location, a large general hospital 
and a long term care facility were monitored.
In the Scottish Borders region the project monitored the largest 
hospital complex in the area (UK - 1), housing medical, surgical, 
geriatric, paediatric, stroke, palliative care, gynaecological, and labour 
wards, as well as 5 theatres and A&E. There was also a restaurant in 
the building. The main hospital building has 300 beds and occupancy 
in 2009/10 was 77%. Water usage for the entire complex (including 
the lodges, laundry, crèche and residential properties) was 174 m3 day-
1. Within this hospital complex, a smaller sub - catchment (UK - 2) 
serving a geriatric unit (16 beds at 85% occupancy, water usage 2.2 m3 
day-1) and a psychiatric unit (26 beds at 80% occupancy, water usage 6.3 
m3 day-1) were monitored separately. 
The general hospital in the West End of the city of Glasgow (UK - 
3) was monitored for effluent from the main clinical building, housing 
surgical, renal, vascular, orthopaedic, medical, and cardiac wards, an 
intensive therapy unit, a high dependency unit, an X - ray department, 
A&E, as well as a dining room, catering, a shop and an enquiries and 
administrative section. In 2010 - 11 occupancy of its 318 beds was 100% 
and the total supplied volume of water was 214 m3 day-1. Also in the west 
of the city of Glasgow, a 120 beds stroke - , general - and orthogeriatric 
rehabilitation hospital (UK - 4) was monitored. Patients were primarily 
older and in "long - stay" care, although there were also day patient 
services for physiotherapy, podiatry and occupational therapy, and a 
small internal laundrette and canteen. Water consumption in 2010 - 11 
was 9,944 m3 (27 m3 day-1). This was slightly higher than normal due to 
a burst pipe in Nov - Dec 2010.
France
The French case study considered a university hospital centre 
which represented 70% of all clinical activities in Limoges. The hospital 
provided 869 patient beds and the water consumption reached 923 m3 
day-1, with week vs. week - end variation in average inflow ranging from 
814 to 406 m3 day-1, respectively. The hospital effluent samples analysed 
in this study were collected only from clinical activities sewerage of the 
hospital. (Detailed monitoring results not reported in this paper.)
A note on dilution
Expected concentrations in wastewater are influenced by the 
dilution factor provided by water usage in the hospital: higher water 
usage results in reduced concentrations of pollutants in the wastewater. 
As some hospitals had restaurant and/or laundry facilities, and in some 
cases rain water ingress into the sewerage pipes, the wastewater streams 
can be more dilute arriving at the WWTP than based on water usage 
(Table 4).
Sample Collection, Preparation and Analysis 
The scope of this section is to describe, in summary, the general 
analytical chemistry approach undertaken by the partners. Where 
possible, sharing of knowledge and expertise of the partners was 
encouraged, but in the light of reported data on the variability of 
measured concentrations of micropollutants in waste waters and 
existing infrastructure at the various partner laboratories it was decided 
not to develop uniform operating procedures for all partners to follow. 
Instead, each partner developed methods that were appropriate to their 
available equipment and resources, and conducted their own quality 
control.
The raw hospital wastewaters were sampled flow proportionally. 
Subsequent sample processing and “clean - up” procedures used 
by the different partners reflected the varied matrix of the waste 
water sampled. For example, in cases where the waste water that was 
sampled was predominantly completely untreated and came directly 
from sewage outlets (as in the UK), an additional sample clean - up 
procedure was employed. This along with dilution reduced the matrix 
effect and was employed for all UK samples to maintain consistency. 
Where appropriate, isotopically labelled internal standards were added 
in line with general quality assurance procedures.
Sample preparation for analysis involved various processes with the 
general aim of yielding a concentrate of liquid sample that is suitably 
purified and enriched in order to be ready for LC - or GC - MS - MS 
analysis. The waste water samples (up to 1 litre) were filtered to remove 
any suspended particulate matter (typically with 0.2/0.1 micrometres 
filters) and from there the sample, (after addition of internal standards) 
proceeded to clean - up and enrichment. In most cases this included 
the use of Solid Phase Extraction (SPE) media, through which the 
waste water sample was passed at a particular pH. The SPE cartridge 
should retain the pharmaceuticals with the unwanted material passing 
through into the filtrate. Once dried the SPE cartridges were first 
washed with water, then treated with a small volume of organic solvent 
e.g. methanol or acetonitrile to elute the pharmaceuticals. The samples 
were then dried down under a stream of nitrogen and reconstituted 
in solvent. If starting from 1 litre and reconstituting in 1ml this gives 
a 1,000 fold enhancement in concentration. In samples from dirtier 
sources this required further clean - up by supported liquid extraction 
cartridges (SLE) and dilution to further reduce matrix effect. Most 
partners applied SPE techniques, and the Swiss partner used an online 
- SPE followed directly by the separation and detection with LC - MS 
- MS [45]. 
The extracts were analysed by LC - MS - MS and GC - MS - MS. 
The majority of partners used LC - MS - MS with selected reaction 
monitoring mode (SRM mode) for specificity. Where available, 
isotopically labelled internal standards were used, to correct for losses 
during the extraction and interferences during analysis. Other quality 
assurance procedures such as the determination of recoveries and 
limit of quantitation were employed in order to test the validity of the 
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analysis. Calibration standards were prepared covering the expected 
concentrations for each analyte. The concentration of pharmaceuticals 
in waste water was calculated based on internal standard and recovery 
data as appropriate.
Results and Discussion
Priority pharmaceuticals selected for monitoring
As outlined above, the final selection of pharmaceutical substances 
to be included in the monitoring campaigns was based on literature 
data, existing priority lists, national consumption patterns and expert 
input (Table 3). The selection process considered and amalgamated 
data from CH (Switzerland), DE (Germany), NL (the Netherlands), FR 
(France), LU (Luxemburg) and UK (Scotland). Representation of the 
major clusters of pharmaceutical substances was sought: Anaesthetics; 
Analgesics/anti - inflammatories; Antibiotics/antibacterials; Anticon-
vulsants/tranquilisers; Beta blockers and anti - hypertensive; Contrast 
media; Cytostatics; Lipid regulators.
Retrospectively, the PILLS selection was also cross referenced with 
a study commissioned by the Global Water Research Coalition GWRC 
[27]. This study yields a representative and qualitative profile (‘umbrella 
view’) of priority pharmaceuticals based on an extensive set of criteria 
and data derived from 25 previous prioritisation studies. It identifies 
10 High Priority Pharmaceuticals, 18 Priority Pharmaceuticals and 16 
Lower Priority Pharmaceuticals. De Voogt [27], selected the following 
criteria: regulation, consumption/sales, physico - chemical properties, 
degradability/persistency, human toxicity, ecotoxicity, occurrence in 
groundwater/surface water/drinking water, occurrence in wastewater. 
A high correlation with the GWRC priority setting was observed, 
validating the partners’ choices. Eight out of the ten High Priority 
Pharmaceuticals feature in the PILLS selection; only ibuprofen and 
gemfibrocil do not. Both are widely used in the community. The PILLS 
project had a different focus, in that it primarily considered the hospital 
environment, that it had hospital contribution (to the total load for 
each compound) as a separate criterion and that the availability of an 
analytical method was also considered. All other compounds on the 
PILLS list were listed as Priority Compounds by De Voogt et al. [27] 
except lidocaine, iopamidol and ifosfamide. All of these are considered 
typical hospital drugs and were therefore of special interest to the 
project. Additional correlations can be found with the priority lists 
mentioned by Umweltbundesamt [49], Götz et al. [50], UBA [51], 
Bergmann [52] and Fick et al. [53].
Pharmaceutical residue from hospitals
Consumption: For the selected compounds, pharmaceutical 
usage data was obtained as annual totals of prescribed medicine at the 
selected hospitals (Table 4); UK rural annual amounts dispensed in the 
community, per head of population, are shown for comparison.
Variation (daily and weekly) and mass balances: High variation 
in concentrations and loads were encountered when analysing hospital 
wastewater day by day over a one - week period. Short - term variation 
will exist where certain treatments are only carried out on certain 
days of the week e.g. less contrast media were found at weekends. The 
comparison of the rural UK hospital and the associated WWTP over 
the same period similarly indicated some daily variation - interestingly 
also for the WWTP - and a significantly higher concentration of some 
compounds in WWTP than in the hospital effluent. Interviews with 
hospital staff (UK rural) suggest that both pharmaceutical use and 
water consumption vary on different days of the week. Around 25% 
of patients at the psychiatric facility go home during the weekend, staff 
at the radiology department stated weekends are ‘much quieter’ than 
weekdays and the outpatients unit is open from Monday to Friday only. 
It is therefore likely that certain pharmaceuticals are consumed less 
during the weekends. On the other hand, laundry, which accounted 
for 29% of water consumption in 2009/10, is done on weekdays and 
Saturday mornings, but not on Sunday, which could lead to increased 
concentrations of pharmaceutical residue measured on Sundays. 
Further investigation would be necessary to verify and quantify these 
effects analytically. Similarly, comparison of data for atenolol and 
carbamazepine, based on analysis of weekly composite samples taken 
on the same weekdays over a period from October 2010 to March 2011, 
showed a tenfold variation in effluent concentration from around 60 to 
600 mg bed-1 day-1.
As would have been expected, there is a tendency for the reliability 
of mass balances (consumption vs. measured values) to increase with 
a longer observation period. A more levelled - out consumption was 
observed for substances which are applied widely and/or in high loads 
like sulfamethoxazole or carbamazepine. For other substances like 
cyclophosphamide, which are often applied for individual therapies 
to single patients and in small dosages, it was much harder to get a 
reliable mass balance (PILLS, 2012). Overall, there was considerable 
uncertainty and inaccuracy due to:
•	  Variability in excretion rates (e.g. different administration 
routes); 
•	  Substances prescribed but not excreted in the hospital or vice 
versa;
•	  Substances prescribed but not used;
•	  Infrequently used substances and substances present at 
concentrations close to the detection limit, due to high 
dilutions/ low use.
Hospital contribution: Three partners collected data on 
the contribution that their partner hospitals made to the overall 
pharmaceutical loading at the receiving WWTPs. DE and LU did so 
by comparing measured pharmaceuticals in hospital wastewater and 
in WWTP influents; UK used pharmaceutical consumption data. The 
calculated hospital contributions varied between the three areas, even 
though they showed generally higher values for specific substances 
such as X - ray contrast media (Table 4). It has to be noted that the 
results were obtained against a number of uncertainties as regards 
prescription to in - or out - patients, behaviour in sewer, and flow - 
measurement, on top of the challenging analysis of micro - pollutants 
in a very dirty aqueous matrix. As such, the contribution results can 
be seen only as an indication (e.g. >100% contribution for Iopamidol). 
Residential care facilities: The UK rural residential care facility 
(UK - 2, Table 4), comprising geriatric and psychiatric residential 
facilities, has notably lower consumption of antibiotics per bed than the 
general hospitals and pharmaceutical usage per bed was considerably 
higher than average for people living in the community. Apart from the 
residential geriatric hospital, there are also four care homes for older 
people, with a total of 125 beds, connected to the receiving WWTP. 
Pharmaceutical consumption in care homes for older people can be 
expected to be lower than in geriatric hospitals, as, over a range of 
residential facilities open to elderly people, the geriatric hospital is 
likely to cater for those with the most serious health issues. For this 
catchment, the number of care home beds is considerably lower 
than the number of hospital beds connected to the WWTP and, with 
pharmaceutical consumption also generally lower than in general 
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†It was agreed that Amoxicillin would be of interest, but there were concerns over the analyte stability. It was nonetheless planned to be monitored by 5 out of 6 partners 
and has therefore been left in the data tables accompanying this paper 
‡Including the metabolite N - acetyl - sulfamethoxazole. Excretion of sulfamethoxazole is mainly in the form of the metabolite but there is a degree of conversion back to the 
parent compound during wastewater treatment, so that parent compound and metabolite need to be included in mass balances (Göbel et al., 2005)
Table 3: Compounds selected for monitoring.
Pharmaceutical class Compound Reason for inclusion  Notes
Analgesics and anti-
inflammatories Naproxen
•	 Identified by 4 partners
• MEC of 9300ng/l (Zorita et al., 2009)
• found in waste water and surface water (CH, 
NL)
• up to 30% hospital contribution
Analgesics, or pain killers, are widely used and have been measured in 
high concentrations in sewage influent and effluent, as well as in surface 
waters (Derksen et al, 2001). For some analgesics (e.g. Paracetamol and 
Ibuprofen) the hospital contribution is relatively small as these compounds 
can be bought over the counter, so that they were not monitored even 
though they pose an environmental risk.
Diclofenac
•	 selected by 5 partners
•	 high consumption (CH, NL)
• highest acute toxicity of non-steroidal anti-
inflammatory drug (NSAID) (Fent et al., 2006)





•	 selected by 4 partners
•	 on 5 priority lists
•	 persistent in standard waste water treatment 
(e.g. Ferrari et al., 2003)
Carbamazepine is not a typical hospital drug, but has been previously 




•	 Selected by 3 partners
•	 Found in wastewater (CH)
•	 on 3 priority lists
Betablockers are not typical hospital drugs, but may be used in above 
average amounts in care homes; atenolol was selected as a representative
Lipid Regulators Bezafibrate
•	 Selection by 4 partners
•	 Found in wastewater (CH)
•	 on 5 priority lists
Chronic exposure to these compounds did show inhibition of growth 
population on rotifers and crustaceans at lower concentrations, whereas 
acute toxicity was in the order of dozens of mg/L. Genotoxic and mutagenic 
effects were especially found for gemfibrocil and its by-products (Isidori et 
al., 2007).
Anaesthetics Lidocaine
•	 Selected by 3 partners
•	 Found in wastewater (CH)
•	 Widely used anaesthetic
•	 Expected high hospital contribution
Lidocaine is a widely used anaesthetic and expected to have a high 
hospital contribution. 
Antibacterials Amoxicillin†
•	 selected by 4 partners
•	 high concentrations expected
•	 most used antibacterial (NL)
Antibacterials are a diverse group of chemicals that can be divided 
into subgroups such as β-lactams (including penicillins), quinolones, 
tetracyclines, macrolides, sulphonamides and others. In most countries, 
β-lactams account for approximately 50-70% of antibacterials. Some 
sorption to sludge occurs, but biodegradation is poor for most antibacterials 
(Kümmerer, 2009a).  The concentrations reported for β-lactams are low 
compared to those expected given the extensive use; this could be due to 
analytical difficulties (Kümmerer, 2004)  because β-lactams are not very 
stable and readily hydrolyse  (Hirsch et al., 1999; Längin et al., 2009). 
According to literature, the hospital contribution to total environmental load 
varies between only a few percent and over 80% (Ternes and Joss, 2006).
Ciprofloxacin
•	 selected by 4 partners
•	 most used fluoroquinolone (NL, CH)




•	 selected by 4 partners
•	 most frequently used macrolide (NL)
•	 found in wastewater (CH)
•	 low PNEC
Erythromycin •	 selected by 5 partners
•	 on 5 priority lists 
Sulfameth 
oxazole‡
•	 selected by 5 partners
•	 high concentrations expected (NL)
•	 top sulfanomide (NL)
•	 4 priority lists (DE) 
•	 found in wastewater (CH)
Contrast media Diatrizoate •	 selected by 5 partners
•	 on 4 priority lists Most contrast media are water soluble and are typically complex iodinated 
compounds.  All tend to be excreted almost 100% and be persistent, 
and were included as hospital specific substances even though they are 
designed to be biologically inert.
Iopamidol •	 selected by 4 partners
•	 on 3 priority lists
Iopromide •	 selected by 4 partners
•	 on 3 priority lists
Cytostatics Cyclophos phamide
•	 selected by 4 partners
•	 highly persistent in waste water (Buerge et al., 
2006)
•	 3 priority lists 
Cytostatics, or anti-neoplastics, are anti-cancer drugs and may have 
carcinogenic, mutagenic, fetotoxic and teratogenic effects (Kümmerer et 
al., 1997) even though only at high concentrations (Ferk et al., 2009). They 
are generally persistent and the widely used antineoplast Ifosfamide was 
was found not to be eliminated by conventional treatment (Kümmerer et al., 
1997). Ifosfamide
•	 selected by 4 partners
•	 highly persistent in waste water (Buerge et al., 
2006) 
•	 3 priority lists 
Other treatment 
groups/PPCPs 
considered but not 
included in monitoring 
programme
•	 Other substances such as psycho-active (Care Commission and Mental Welfare Commission, 2009), anti-viral and anti-diabetic drugs 
were suggested for monitoring but are primarily used in the community and was therefore less relevant to the project. Other compounds 
suggested by the partners included preservatives, diuretics, anti-fungals, disinfectants, antacids and anti-worming agents.
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†During measurement campaigns: DE: Sampling period 31.01.2011 - 07.02.2011, n=7, 24h composite samples (flow proportional); LU: Sampling period 18.10.2010 
- 22.10.2010, n=10, 24h composite samples (time proportional); FR: Sampling period 23.06.2010 - 12.07.2010, n=7, 24h composite samples (time proportional); UK: 
Sampling period 09.2010 - 02 - 2012, weekly composite samples (flow proportional). Hospitals:1 - Rural general, n=46; 2 - Rural long term, n=10; 3 - Urban general, n=48; 
4 - Urban long term, n=37; 5 - Community prescribed in rural catchment, per head of population for calendar year 2010.
‡Calculated based on: DE and LU: Flow proportional sampling in hospital effluents and comparison with prescription data, sampling periods as above; UK: Dispensed 
pharmaceuticals to the rural hospital complex (inc. psychiatric and geriatric lodges but excluding outpatient prescriptions) compared to the community prescribed 
pharmaceuticals in the region (pro - rata for catchment size). Only calculated for hospitals that were sole (hospital) contributors to a monitored sewer flow.
n.a. = not analysed ; LOQ = limit of quantitation; substances detected but not quantifiable
Table 4: Annual pharmaceutical consumption and hospital contribution to load in sewers.
Hospital pharmaceutical consumption [gbed - 1a - 1]† Community 
[gp - 1a - 1]
Hospital contribution to 
WWTP load [%]‡General hospital Long term care
DE LU FR NL UK - 1 UK - 3 UK - 2 UK - 4 UK - 5 DE LU UK - 1 
Year 2011 2010 2010 Mean 2011 2011 2011 2011 2010
Water usage 
[‘000 m3a - 1] 73.0 51.4 157.2 87.6 63.8 47.4 3.1 9.4  - 
WWTP catchment [‘000 p] 77 47 14
Hospital flow contribution [%] 0.8 1.5 6.9
Beds per 1000 inhabitants 7.3 11.9 22.0
No. of beds 560 360 863 1076 265 318 34 120  - 
Diclofenac 7.07 1.62 1.93 0.50 3.26 3.98 0.30 0.19 0.65 2.9 5.5 8.5
Naproxen 0.00 8.73 2.18 0.07 3.98 1.85 8.87 0.44 1.34 1.2 11.2 5.3
Carbamazepine 1.64 1.00 2.91 0.00 4.34 4.49 3.78 1.87 0.72 4.4 21.4 10.1
Atenolol 0.27 0.15 0.64 0.00 2.20 1.59 1.19 0.47 0.63 1.0 1.9 6.1
Bezafibrate 0.84 0.00 0.00 0.01 0.78 0.41 0.23 0.00 0.17 2.1 n.a. 8.0
Lidocaine 0.00 2.21 46.95 2.36 17.21 8.45 0.06 0.36 0.07 n.a. 61.2 81.3
Amoxicillin 22.73 92.52 67.05 47.49 72.26 125.37 8.53 21.52 1.87 1.0 n.a. 42.0
Ciprofloxacin 9.61 16.50 21.80 8.96 27.31 24.19 1.45 1.32 0.17 11.8 154.6 74.8
Clarithromycin 3.82 5.47 0.85 0.40 24.75 18.04 1.76 1.33 0.40 59.1 18.2 36.0
Sulfamethoxazole 3.32 0.33 13.39 5.37 0.00 15.07 0.00 1.33 0.03 4.7 53.0 0.0
Erythromycin 2.18 0.55 2.93 1.45 2.12 2.41 6.50 0.00 0.45 82.4 64.3 8.1
Diatrizoate 67.06 0.00 181.37 3.89 0.00 29.45 0.00 0.53 0.00 67.8 n.a. 0.0
Iopamidol 13.49 0.00 4.36 0.00 687.67 9.63 0.00 0.00 0.00 77.8 n.a. 100
Iopromide 0.00 0.00 0 248.42 4.26 0.00 0.00 0.00 0.00 0.1 n.a. 100
Cyclophosphamide 0.31 0.48 1.79 1.94 0.00 8.45 0.00 0.00 0.00 < LOQ 12.7 0.0
Ifosfamide 0.10 0.28 0.71 0.03 0.18 0.00 0.00 0.00 0.00 < LOQ n.a. 100
hospitals, the care home contribution is expected to be less important 
than the (general) hospital contribution. This expectation is further 
supported by considering that a relatively high number of elderly 
people in residential care will be using incontinence pads. However, 
in other WWTP catchments the number of care home beds may be far 




Literature data relating to occurrence and environmental risk are 
complex, with the parameters identified as relevant for the selection 
process being: hospital contribution, usage, excretion rate, removal 
rate in WWTP, and PNEC value.
Several of these parameters were difficult to quantify especially 
in the context of local point sources within the healthcare sector. 
Pharmaceuticals occurrence in surface waters will vary from location 
to location, and possibly also seasonally. Excretion occurs over time, 
and hospital usage does not necessarily lead to excretion into hospital 
wastewater. Removal rates vary with a number of environmental and 
process parameters, resulting in significant variation in efficiencies 
between treatment plants and within the same plant over time. PNEC is 
well defined but variations of up to a factor 1000 are encountered within 
the literature depending on endpoint (e.g. morphology, reproductive 
rate or behaviour) and study conditions; whilst a precautionary 
approach suggests using the lowest published value, this can lead to 
overestimation of risk and introduce uncertainty in the comparison 
and interpretations of results. 
Hospital effluent concentrations and contributions
Consumption (by weight) of the pharmaceuticals under 
investigation in the hospitals was highest for contrast media (for single 
compounds up to 981 gbed-1a-1), while antibacterials generally also had 
relatively high consumption figures (typically 5 - 25 gbed-1a-1). 
For the WWTPs, hospitals and specific compounds investigated, 
hospital contributions to the total load of pharmaceutical in the WWTP 
influents showed considerable variation – both between compounds 
and hospitals - but were highest for contrast media, lidocaine and 
antibacterials, in particular ciprofloxacin and clarithromycin. Hospital 
contributions for compounds for other treatment groups were below 
20%.
The research did not indicate that residential care facilities are 
likely to be a significant source of pharmaceutical pollution, but as only 
one partner investigated residential care facilities a general statement 
cannot be made.
Due to the variability between the considered hospitals, and 
also between different samples from the same hospital, a general 
characterization of hospital wastewaters is hard to achieve. However, 
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with detailed consumption data a good prediction of pharmaceutical 
loads in hospital effluents can be achieved (PILLS, 2012). A reliable 
mass balance requires detailed acquisition of data at hospital level and 
proper continuous sampling over a longer time period involving flow 
proportional sampling.
Method development and outlook
Overall, this project showed that hospitals can be a significant point 
source for selected pharmaceutical micro - pollutants in the water 
environment. The project also showed that treatment at source can 
be one way to deal with such pollutants [54] but that other means to 
deal with this issue may be required: prescription patterns, consumer 
behaviour or centralised treatment may all be targeted if there is a 
political will to reduce this type of pollutant. 
However, against a background of rising awareness of - and 
quality standards for - micropollutants of various types, it may become 
necessary to gain far more detailed understanding of emission pathways 
within the urban environment.
Our approach towards the identification of suitable priority (or 
indicator) substances for monitoring at specific point sources appears 
to be validated by the results. We tried to start with a traditional risk 
assessment approach comprising data collection on consumption, 
removal, PEC calculation and comparison with PNEC, but this was 
not feasible due to lack of data. Our method was therefore, necessarily, 
an attempt to deal with uncertainty and incomplete data sets, and we 
would argue that method is valid in situations where specific data sets 
are not available. We are acutely aware of the aversion that this will 
cause with most natural science practitioners but we feel that the topic 
does require a certain openness to embrace uncertainty. Otherwise, 
prioritisation will be constrained to drawing on the same existing lists 
over and over, as new information is being created very slowly and new 
information is unlikely to be created for substances that have not been 
identified for monitoring or as emerging priorities. 
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